The % JAK2 V617F was notably higher in patients with PV (mean (SD) = 52.11% (25.46)) and PMF (mean (SD) = 51.20% (27.16)) compared to those with ET (mean (SD) = 26.60% (21.08)) (Table 3). This evidence concerns the gene JAK2 and essential thrombocythemia.